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Introduction
Extubation failure in critically ill patients has associated
morbidity, but it cannot be safely predicted or avoided.
Preventive NIMV has proved beneficial only in hyper-
capnic patients. We hypothesized that High-flow oxygen
therapy may reduce postextubation respiratory failure
due to gas humidification, avoidance of lung collapse by
moderate PEEP, and work of breathing reduction by
dead-space washing.
Objectives
Our objective was to reduce postextubation respiratory
failure with High-flow in high-risk patients.
Methods
Randomized multicenter trial in patients who successfully
passed a spontaneous breathing trial. Only patients with
criteria for high-risk of failure were randomized to receive
conventional oxygen or High-flow oxygen (Optiflow®:
Fisher Paykel) for 24 hours post-extubation. Primary
outcome was respiratory failure within 72 hours postextu-
bation. Secondary outcome were: reintubation, ICU and
hospital length of stay, and survival. Statistical analysis
included multiple logistic regression models.
Results
The study was stopped after 18 months due to low recruit-
ment. We enrolled 155 patients: 77 with conventional and
78 with High-flow oxygen. Groups were very similar at
enrollment. All patients tolerated the High-flow system.
We found the projected reduction in postextubation
respiratory failure (20.5% vs. 27.3%, p = 0.3) that failed to
reach statistical significance due to sample size. Similarly,
the benefit in reintubation (16.7% vs. 19.5%, p = 0.6) didn´
t reach significance. We found no differences in ICU
length of stay, hospital length of stay, and survival. By a
logistic regression model, we were able to independently
associate high-flow with reduction in postextubation
respiratory failure (OR 0.4 p = 0.049), by including COPD,
cancer, length of MV, obesity, and cardiac failure in the
model.
Conclusions
High-flow oxygen therapy for 24-h may reduce postextu-
bation respiratory failure in high-risk critically ill patients.
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